The Landscape of Pharmacotherapeutic Development in the NIDA Small Business Program

See tables below
The NIDA Small Business Drug Discovery and Development Program landscape from 2016-2023 categorizes molecules by their development stages, as detailed in NIH Reporter project descriptions. These stages include Target Identification and Validation, Lead Generation and Optimization, Preclinical Development, and Phase I, Phase II, and Phase III clinical studies. Additionally, molecules are classified by their indications: Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder, Overdose Reversal Agents, and Tobacco Use Disorder. Other DSM-5 substance use disorders are not included. This depiction is not exhaustive.

OTIPI Therapeutics Pipeline

Opioid Use Disorder
Target ID and ValidationLead Generation and OptimizationPreclinical DevelopmentPhase I

If you have questions, please contact Tam Nguyen or Boris Sabirzhanov

Overdose Reversal Agents
Target ID and ValidationLead Generation and OptimizationPreclinical DevelopmentPhase I
 

If you have questions, please contact Tam Nguyen or Boris Sabirzhanov

Stimulant Use Disorder
Target ID and ValidationLead Generation and OptimizationPreclinical DevelopmentPhase I
 

If you have questions, please contact Saru Karuppagounder

Cannabis Use Disorder
Target ID and ValidationLead Generation and OptimizationPreclinical DevelopmentPhase I
  

If you have questions, please contact Saru Karuppagounder

Tobacco Use Disorder
Target ID and ValidationLead Generation and OptimizationPreclinical DevelopmentPhase II

If you have questions, please contact Tam Nguyen